Welcome to our dedicated page for Athira Pharma SEC filings (Ticker: ATHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Athira Pharma, Inc. (NASDAQ: ATHA) SEC filings page brings together the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Athira, which has announced a name change to LeonaBio, Inc. with a future ticker "LONA," uses filings such as Forms 8-K and 8-K/A to report material events related to its operations, capital structure and key licensing agreements.
Recent filings describe a 10-for-1 reverse stock split of common stock, implemented through a certificate of amendment in Delaware, and subsequent confirmation from The Nasdaq Stock Market that Athira regained compliance with the minimum bid price requirement. Other 8-K filings detail a private placement financing involving common stock, pre-funded warrants and accompanying common warrants, with gross proceeds expected to be approximately $90 million, and outline associated registration rights for investors.
Filings also cover Athira’s exclusive licensing arrangements for lasofoxifene with Sermonix Pharmaceuticals and Ligand Pharmaceuticals, including the assumption of responsibility for the global Phase 3 ELAINE-3 trial outside specified retained territories. These documents provide insight into how the company structures rights to develop, manufacture and commercialize oral forms of lasofoxifene and how it coordinates with partners.
On this page, users can review Athira’s current reports to understand how financing terms, warrant structures, reverse stock split mechanics and licensing obligations interact with its clinical programs in metastatic breast cancer and ALS. Stock Titan’s platform adds AI-powered summaries to help explain the key points of lengthy filings, highlight important dates and thresholds, and make it easier to interpret how each filing may relate to Athira/LeonaBio’s broader strategic and clinical plans.
Athira Pharma, Inc. is implementing a 10-for-1 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern Time on September 17, 2025. This means every ten existing shares will be combined into one share, while the par value per share remains $0.0001.
The company is also reducing its authorized common stock from 900,000,000 to 90,000,000 shares and total authorized capital stock from 1,000,000,000 to 190,000,000 shares. Athira’s common stock is expected to begin trading on a post-split basis on The Nasdaq Capital Market on September 18, 2025 under the symbol ATHA.
Fractional shares resulting from the reverse split will be settled in cash, and proportional adjustments will be made to outstanding options, restricted stock units, and equity plan reserves. Stockholders holding shares in book-entry or through brokers will have their holdings automatically adjusted without needing to take action.
Athira Pharma, Inc. (NASDAQ: ATHA) has filed a Form 144, disclosing a proposed sale of 25,123 common shares through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, on or about 01 Jul 2025. These shares equal roughly 0.06 % of the company’s 39,042,445 shares outstanding.
The shares were acquired on 30 Jun 2025 via a “Restricted Stock Lapse” tied to equity compensation. No other sales by the same insider have occurred in the past three months according to the filing. Aggregate market value is listed as 7,374 (units not specified). The sale will be executed on the NASDAQ exchange.
Because the transaction size is immaterial compared with ATHA’s float and no identity or role of the seller is provided, the filing is generally viewed as routine rather than a signal of strategic or operational change. Form 144 merely gives notice of intent; the sale may or may not ultimately occur. Investors may interpret the filing as normal portfolio or tax management following the vesting of stock-based compensation, rather than a negative assessment of Athira Pharma’s prospects.
Athira Pharma, Inc. (ATHA) has filed a Form 144 indicating an insider’s intention to sell shares. The notice covers the proposed sale of 10,842 common shares through Morgan Stanley Smith Barney on or after 01 July 2025. The shares were originally acquired on 30 June 2025 via the lapse of restrictions on equity compensation, as disclosed in the filing’s “Nature of Acquisition Transaction.”
With 39,040,945 shares outstanding, the proposed sale represents only about 0.03 % of total shares, suggesting minimal dilution or market overhang. There were no other sales reported in the past three months by the same filer. The filing also certifies that the seller is unaware of any material, non-public adverse information about the company.
Form 144 filings are routine compliance documents required when affiliates intend to sell restricted or control stock. While they do not guarantee a sale will occur, they provide advance notice to the market. Because the volume is small relative to shares outstanding and there are no accompanying negative disclosures, the near-term impact on ATHA’s share price is likely limited. Nevertheless, investors often watch insider activity for sentiment signals; the timing—immediately after a restriction lapse—may be interpreted as profit-taking by the holder.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
